Captrust Financial Advisors Takes Position in AtriCure, Inc. (NASDAQ:ATRC)

Captrust Financial Advisors acquired a new stake in AtriCure, Inc. (NASDAQ:ATRC) in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 8,191 shares of the medical device company’s stock, valued at approximately $230,000.

Several other large investors also recently made changes to their positions in ATRC. Comerica Bank boosted its holdings in shares of AtriCure by 70.5% in the 1st quarter. Comerica Bank now owns 2,522 shares of the medical device company’s stock valued at $77,000 after buying an additional 1,043 shares during the last quarter. Panagora Asset Management Inc. raised its stake in AtriCure by 8.2% in the 2nd quarter. Panagora Asset Management Inc. now owns 309,547 shares of the medical device company’s stock valued at $7,048,000 after acquiring an additional 23,436 shares during the period. HighMark Wealth Management LLC raised its stake in AtriCure by 664.1% in the 2nd quarter. HighMark Wealth Management LLC now owns 69,725 shares of the medical device company’s stock valued at $1,588,000 after acquiring an additional 60,600 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A. raised its stake in AtriCure by 0.8% in the 2nd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 380,720 shares of the medical device company’s stock valued at $8,669,000 after acquiring an additional 2,898 shares during the period. Finally, Rhumbline Advisers raised its stake in AtriCure by 3.7% in the 2nd quarter. Rhumbline Advisers now owns 72,936 shares of the medical device company’s stock valued at $1,661,000 after acquiring an additional 2,577 shares during the period. Institutional investors and hedge funds own 99.11% of the company’s stock.

AtriCure Stock Down 3.4 %

Shares of NASDAQ ATRC opened at $31.67 on Monday. The company has a debt-to-equity ratio of 0.13, a quick ratio of 2.59 and a current ratio of 3.62. AtriCure, Inc. has a 52 week low of $18.94 and a 52 week high of $39.04. The stock has a market capitalization of $1.54 billion, a P/E ratio of -38.16 and a beta of 1.40. The stock’s fifty day moving average is $32.93 and its 200 day moving average is $27.25.

AtriCure (NASDAQ:ATRC) last announced its quarterly earnings results on Tuesday, October 29th. The medical device company reported ($0.17) EPS for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.02. AtriCure had a negative return on equity of 8.12% and a negative net margin of 8.70%. The firm had revenue of $115.91 million for the quarter, compared to analyst estimates of $112.23 million. During the same period last year, the firm posted ($0.20) earnings per share. The business’s revenue for the quarter was up 17.9% on a year-over-year basis. Sell-side analysts forecast that AtriCure, Inc. will post -0.72 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the company. StockNews.com upgraded AtriCure from a “sell” rating to a “hold” rating in a research note on Saturday, September 14th. Oppenheimer increased their price target on AtriCure from $32.00 to $36.00 and gave the company an “outperform” rating in a research note on Wednesday, October 30th. Canaccord Genuity Group increased their price target on AtriCure from $53.00 to $61.00 and gave the company a “buy” rating in a research note on Monday, December 9th. UBS Group increased their price target on AtriCure from $35.00 to $40.00 and gave the company a “buy” rating in a research note on Wednesday, October 30th. Finally, JPMorgan Chase & Co. increased their price objective on AtriCure from $30.00 to $40.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 30th. One research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $42.00.

About AtriCure

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.